Particle therapy in Europe

Grau, Cai; Durante, Marco; Georg, Dietmar; Langendijk, Johannes A.; Weber, Damien Charles

doi:10.1002/1878-0261.12677

Cited by 72 publications

(57 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunological interventions with checkpoint inhibitors, antibodies, vaccination programmes and cell therapies show ample promise [36][37][38][39][40]. In addition, developments in radiobiology and radiophysics have boosted innovation in radiation therapies; for example, novel fractionated radiation regimens, use of different sources (photons, protons and light ions), or combination with other treatments offer new perspectives [41][42][43][44][45]. Surgical treatment is moving towards technologies with improved preservation of organ function and integration with both radiation therapy and medical anticancer treatment [41,46].…”

Section: Development Of New Therapiesmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

View full text Add to dashboard Cite

A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer researchcare-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidencebased advice.

show abstract

Section: Development Of New Therapiesmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Applications of ion beams in multidisciplinary physics are a long-standing tradition of LNL. These activities are carried out mainly at the AN2000 10 and CN 11 Van de Graaff accelerators and partly at the Tandem 12 . The CN (1-6 MV) and AN2000 (0.2-2.2 MV) provide a total of 12 beamlines and deliver around 2,700 h/year of beamtime ( 1 H, 2 H, 3 He, 4 He, 14 N, and 15 N).…”

Section: Infn and Cnaomentioning

confidence: 99%

“…BNCT has been hampered by the necessity of using nuclear reactors for treatment but is now revived by the perspective of using dedicated proton accelerators [10]. Cyclotrons and synchrotrons for charged-particle therapy are blooming worldwide [11][12][13], and many of these centers have intense preclinical research programs [14]. Research in space radiation protection also needs accelerators to simulate the cosmic radiation that astronauts find in the space environment [15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Biomedical Research Programs at Present and Future High-Energy Particle Accelerators

et al. 2020

Self Cite

View full text Add to dashboard Cite

Biomedical applications at high-energy particle accelerators have always been an important section of the applied nuclear physics research. Several new facilities are now under constructions or undergoing major upgrades. While the main goal of these facilities is often basic research in nuclear physics, they acknowledge the importance of including biomedical research programs and of interacting with other medical accelerator facilities providing patient treatments. To harmonize the programs, avoid duplications, and foster collaboration and synergism, the International Biophysics Collaboration is providing a platform to several accelerator centers with interest in biomedical research. In this paper, we summarize the programs of various facilities in the running, upgrade, or construction phase.

show abstract

“…There is a growing investment in proton and heavy ion therapy worldwide, with 89 proton centers and 12 carbon centers currently in clinical operation [according to the Particle Therapy Co-Operation Group (PTCOG)] [1]. Of these worldwide facilities, 31 proton centers (∼35%) and four carbon centers (∼33%) are located in Europe [2]. Despite the increasing adoption of particle therapy there remains a number of unanswered questions about this relatively new treatment modality [3].…”

Section: Introductionmentioning

confidence: 99%

Mapping the Future of Particle Radiobiology in Europe: The INSPIRE Project

et al. 2020

Self Cite

View full text Add to dashboard Cite

Particle therapy is a growing cancer treatment modality worldwide. However, there still remains a number of unanswered questions considering differences in the biological response between particles and photons. These questions, and probing of biological mechanisms in general, necessitate experimental investigation. The "Infrastructure in Proton International Research" (INSPIRE) project was created to provide an infrastructure for European research, unify research efforts on the topic of proton and ion therapy across Europe, and to facilitate the sharing of information and resources. This work highlights the radiobiological capabilities of the INSPIRE partners, providing details of physics (available particle types and energies), biology (sample preparation and post-irradiation analysis), and researcher access (the process of applying for beam time). The collection of information reported here is designed to provide researchers both in Europe and worldwide with the tools required to select the optimal center for their research needs. We also highlight areas of redundancy in capabilities and suggest areas for future investment.

show abstract

Particle therapy in Europe

Cited by 72 publications

References 40 publications

Towards a cancer mission in Horizon Europe: recommendations

Towards a cancer mission in Horizon Europe: recommendations

Biomedical Research Programs at Present and Future High-Energy Particle Accelerators

Mapping the Future of Particle Radiobiology in Europe: The INSPIRE Project

Contact Info

Product

Resources

About